Klin Farmakol Farm. 2025;39(3):145-149 | DOI: 10.36290/far.2025.056

Beta-blockers in the treatment of chronic coronary artery disease

Martin Ambroz, Ondřej Ludka
Všeobecná interní klinika, Fakultní nemocnice Brno
Lékařská fakulta Masarykovy univerzity, Brno

Beta-blockers (BB) represent one of the key groups of drugs in the treatment of chronic coronary artery disease. Pharmacological treatment with BB includes symptom-controlling therapy and prognosis-improving therapy in certain groups of patients. The benefit of BB has been demonstrated in patients with reduced left ventricular ejection fraction (LVEF), but there is a lack of clear data from randomised clinical trials in patients with LVEF > 40 %. Recent studies REDUCE-AMI and ABYSS have attempted to assess the effect of BB in this patient group, but the results were quite contradictory. Chronic coronary artery disease is a heterogeneous disease that requires an individualised approach to the choice of the appropriate active agent, considering the patient's comorbidities, pharmacological properties of the agent, and clinical form of the disease.

Keywords: beta-blockers, chronic coronary artery disease, chronic coronary syndrome.

Accepted: October 23, 2025; Published: October 30, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ambroz M, Ludka O. Beta-blockers in the treatment of chronic coronary artery disease. Klin Farmakol Farm. 2025;39(3):145-149. doi: 10.36290/far.2025.056.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Widimský P, Rychlík I. Vnitřní lékařství: I. díl. Maxdorf; 2023.
    2. Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3415-537. Go to original source...
    3. Táborský M, Kautzner J, Linhart A, et al. Kardiologie: Svazek I-V. Grada Publishing a.s.; 2021.
    4. Safi S, Sethi NJ, Nielsen EE, et al. Beta-blockers for suspected or diagnosed acute myocardial infarction. Cochrane Database Syst Rev. 2019;12(12):CD012484. Go to original source...
    5. Vítovec J. Betablokátory v léčbě kardiovaskulárních onemocnění: Farmakoterapie pro klinickou praxi. Grada Publishing a.s.; 2023.
    6. Khan O, Patel M, Tomdio AN, et al. Beta-Blockers in the Prevention and Treatment of Ischemic Heart Disease: Evidence and Clinical Practice. Heart Views. 2023;24(1):41-49. Go to original source...
    7. Vítovec J, kolektiv. Léčba kardiovaskulárních onemocnění: 2., aktualizované a doplněné vydání. Grada Publishing a.s.; 2020.
    8. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138(13):e272-391. Go to original source...
    9. Ferrari R, Pavasini R, Camici PG, et al. Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment. Eur Heart J. 2019;40(2):190-194. Go to original source...
    10. Sorbets E, Steg PG, Young R, et al. β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. Eur Heart J. 2019;40(18):1399-1407. Go to original source...
    11. Dahl Aarvik M, Sandven I, Dondo TB, et al. Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2019;5(1):12-20. Go to original source...
    12. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. The Lancet. 2001;357(9266):1385-1390.
    13. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-2007.
    14. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106(17):2194-2199. Go to original source...
    15. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13. Go to original source...
    16. Rossello X, Raposeiras-Roubin S, Latini R, et al. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT). Eur Heart J Cardiovasc Pharmacother. 2022;8(3):291-301. Go to original source...
    17. Kim J, Kang D, Park H, et al. Long-term β-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study. Eur Heart J. 2020;41(37):3521-3529. Go to original source...
    18. Rossello X, Pocock SJ, Julian DG. Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care. J Am Coll Cardiol. 2015;66(11):1273-1285. Go to original source...
    19. Cataldo MP, Gasevic D, Trin C, et al. Beta-Blocker Therapy After Myocardial Infarction. JACC: Advances. 2025;4(3):101582. Go to original source...
    20. Watanabe H, Ozasa N, Morimoto T, et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PLOS ONE. 2018;13(8):e0199347. Go to original source...
    21. Yndigegn T, Lindahl B, Mars K, et al. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. N Engl J Med. 2024;390(15):1372-1381. Go to original source...
    22. Bangalore S, Bhatt DL, Steg PG, et al. β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes. 2014;7(6):872-881. Go to original source...
    23. Silvain J, Cayla G, Ferrari E, et al. Beta-Blocker Interruption or Continuation after Myocardial Infarction. New England Journal of Medicine. 2024;391(14):1277-1286. Go to original source...
    24. Munkhaugen J, Ruddox V, Halvorsen S, et al. BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study. Am Heart J. 2019;208:37-46. Go to original source...
    25. Kristensen AMD, Bovin A, Zwisler AD, et al. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial. Trials. 2020;21(1):415. Go to original source...
    26. Motivala AA, Parikh V, Roe M, et al. Predictors, Trends, and Outcomes (Among Older Patients ≥65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights From the NCDR Registry. JACC: Cardiovascular Interventions. 2016;9(16):1639-1648. Go to original source...
    27. Godoy LC, Farkouh ME, Austin PC, et al. Association of Beta-Blocker Therapy With Cardiovascular Outcomes in Patients With Stable Ischemic Heart Disease. JACC. 2023;81(24): 2299-2311. Go to original source...
    28. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018;39(2):119-177. Go to original source...
    29. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2021;42(14):1289-1367. Go to original source...
    30. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal. 2023;44(38):3720-3826. Go to original source...
    31. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9-119. Go to original source...
    32. Vítovec J, Špinar J, Špinarová L. Betablokátory u kardiovaskulárních onemocnění - pro a proti. Kardiologická revue - Interní medicína. 2019(2):86-89.
    33. Shu DF, Dong BR, Lin XF, et al. Long-term beta blockers for stable angina: systematic review and meta-analysis. Eur J Prev Cardiol. 2012;19(3):330-341. Go to original source...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.